The latest progress of the basic medicine directory: the local version is added first, and the national version is promulgated.

The basic drug catalog originally scheduled to be adjusted this year has not seen movement, and the local place took a step ahead.

On July 18, the Xinjiang Health Commission issued an announcement that 27 varieties such as compound artemisia particles and Chai Yin cold particles were included in the basic drug supplement catalog of the autonomous region.

The Jianzhi Bureau noticed that these 27 varieties are basically ethnic medicines, of which 6 are the exclusive varieties of Xinjiang Uygur Pharmaceutical Co., Ltd., a subsidiary of Renfu Pharmaceutical.

In 2019, the National Health and Health Commission stipulated that in principle, the species of drugs were no longer allowed. However, considering the special medication of minorities, these areas can supplement the "small number of ethnic drugs" as needed. This has become the only special case in the adjustment of the base medicine directory.

According to the requirements of the National Health and Health Commission, basic drugs need to be equipped in a certain proportion of secondary and third -level hospitals. For example, the Xinjiang Health and Health Commission requires that the proportion of the amount of basic medicines in the secondary hospital is not less than 50%, and the third -level hospitals are not low. In 30%and increased year by year.

It is difficult to enter the national version of the basic medicine catalog, and local supplements have become an important window for enterprises to do drug access. In order to send their own products into the list of their own thoughts, the company once circulated the rumors of "1 million for a variety".

27 supplements, 6 are exclusive

A small number of ethnic medicines can be added in ethnic minorities. This is the mouth of the National Health and Health Commission in January 2019, but it requires "full demonstration and strict procedures" and strictly control the number of varieties.

Xinjiang's supplemental basic medicines are some commonly used dimensions, 10 of which are from Xinjiang Uygur Pharmaceuticals, and 6 are exclusive varieties, such as the treatment of palpitations and neurasthenia. Magnatan, indigestion, diarrhea and indigestion.

Data source: Xinjiang Health Commission, Xinjiang Uygur Pharmaceutical

According to the company's investigation data, Xinjiang Uygur Pharmaceutical was established in 2001 and is a subsidiary of 73.25%of Renfu Pharmaceutical. In addition, Uyghur Pharmaceutical also has a hospital background. Another shareholder of the company is the Uyghur Medical Hospital of Xinjiang Uygur Autonomous Region, which was founded in 1954. This is a three -way ethnic hospital certified by the State Administration of Traditional Chinese Medicine with 500 beds.

Jianzhi Bureau noticed that in 2018, two cold medicines of Uyghur Pharmaceuticals and Catama Granges and Hanpacu Zopa particles were included in the national basic medicine catalog. In the second year, the revenue of Uyghur Pharmaceuticals rose 24%year -on -year, the highest growth rate reached the highest peak of nearly 7 years.

This time, the 6 core products of Uyghur Pharmaceuticals were included in the local base medicine supplement catalog, and 30%and 50%of the hospital's sales needed to be prescribed. This seems to be guaranteed. It's right.

The situation in Xinjiang is not an example. After the release of national medicine in 2019, Guangxi, Yunnan, Gansu and other places issued documents to launch related work. Qinghai directly stipulated that 100 kinds of Tibetan medicines should be added as basic drugs in the province; Guangxi stated that the autonomous region no longer supplement basic medicines, except for "national medicine."

These ethnic medicines are limited to provinces with a large number of ethnic minorities. The Kenju Bureau has roughly found that at least 18 regions such as Beijing, Henan, Jilin, and Zhejiang have clearly stipulated that the 2018 version of the national medicine catalog is uniformly implemented. Variety.

The national catalog adjustment is as soon as possible, innovative drugs are the biggest highlights

Ethnic medicine has been supplemented, but the National Health and Health Commission said that the national medicine catalog to be adjusted has not been moved until now.

In November 2021, the National Health and Health Commission announced a draft for soliciting opinions to plan to adjust the national basic drug catalog. After the introduction of the basic medicine system, it was only adjusted twice in 2012 and 2018. At present, the latest version of the national medicine directory is included in 685 drugs, including 417 western medicines and 268 Chinese medicines.

The reason why the industry pays attention to the general cheap basic drugs is because when adjusting in 2018, the basic drugs are included in 12 new anti -tumor drugs that are urgently needed, including Geffitinib, Emantinib, Ekntininib, and Lichelliers Monopoly, Telkuzab, Peime Qucei, Cardiabin, etc.

In addition, 11 clinical needed varieties, including Geely's new hepatitis C drugs, phosphorus, Viva Vaeva, or even not even included in medical insurance. It has already entered the 2018 national basic drug catalog, which belongs to "get on the car first, then replenish the ticket". This gives innovative pharmaceutical companies with unlimited reveries on the basic drug directory.

Moreover, in 2019, the General Office of the State Council clearly stipulated that the proportion of basic medicines in primary medical and health institutions, second -level public hospitals, and third -level public hospitals should not be less than 90%, 80%, and 60%, respectively. Entering the base medicine directory can not only solve the problem of "difficulty in entering the hospital", but some provinces also guarantee the proportion of use. This is a good thing for enterprises to ask for.

Not only that, the voices of adjusting the price of basic medicines are getting higher and higher. At the National Council of 2022, Yao Shukun, a member of the National Committee of the Chinese People's Political Consultative Conference and the former vice president of the China -Japan Hospital, proposed that the basic drugs with low prices should be appropriately appropriately picked up and left a reasonable profit for manufacturers.

Several favorable factors have made pharmaceutical companies look forward to the basic drug catalogs that were not noticed.

The industry "implies" the National Health and Health Commission through various occasions to adjust the medical insurance directory in a timely manner. According to the CPPCC website, Gao Tong, vice president of the Lili Lili China Government and Corporate Affairs Department, said: During the reasonable medication of anti -tumor drugs, the national basic drug system has "played an important guiding role." In the future, more innovative drugs should also be included in the basis directory.

However, the basic medicine is not universal.After all, basic drugs are to ensure basic medical needs, and the price and profit level cannot be too high. Although the health system has not carried out a special price limit policy for basic medicines, the new rules are likely to add with the expansion of the basic medicine.

Yao Shukun believes: "If it is an exclusive variety into the basis of the basic medicine, you can consider incorporating alternative medicines that are included in at least one mechanism of the same action." On the one hand, it can be used to competition on the other hand.

Writing ｜ Su Lin

Edit ｜ Jiang Yun Jia Ting

Operation ｜ Valley

Photo Source ｜ Visual China

#Xinjiang Health Commission ## ## National Basic Medicine Catalog ## Xinjiang Uygur Pharmaceutical#

- END -